Joshua Jennings
Stock Analyst at TD Cowen
(3.38)
# 885
Out of 4,843 analysts
68
Total ratings
42.86%
Success rate
5.87%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $4.24 | +253.77% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $325.03 | -0.32% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $105.26 | +4.50% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $16.81 | +114.16% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $127.12 | -5.60% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $2.67 | +274.53% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.66 | +1,779.70% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $58.00 | +70.69% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $92.17 | +29.11% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $41.30 | +45.30% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $84.64 | -5.48% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $17.75 | +153.52% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $78.22 | -10.51% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $155.21 | +19.19% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $30.50 | +31.15% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $382.64 | +4.54% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $34.39 | +74.47% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $19.82 | +71.54% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $5.27 | +241.56% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $85.80 | +45.69% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $21.96 | +13.84% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $133.58 | -2.68% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.13 | +134.74% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $82.98 | +41.00% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $7.54 | +5,868.17% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $12.43 | -3.46% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $172.59 | +59.34% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.24
Upside: +253.77%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $325.03
Upside: -0.32%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $105.26
Upside: +4.50%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $16.81
Upside: +114.16%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $127.12
Upside: -5.60%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $2.67
Upside: +274.53%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.66
Upside: +1,779.70%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $58.00
Upside: +70.69%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $92.17
Upside: +29.11%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $41.30
Upside: +45.30%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $84.64
Upside: -5.48%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $17.75
Upside: +153.52%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $78.22
Upside: -10.51%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $155.21
Upside: +19.19%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $30.50
Upside: +31.15%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $382.64
Upside: +4.54%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $34.39
Upside: +74.47%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $19.82
Upside: +71.54%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $5.27
Upside: +241.56%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $85.80
Upside: +45.69%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $21.96
Upside: +13.84%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $133.58
Upside: -2.68%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.13
Upside: +134.74%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $82.98
Upside: +41.00%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $7.54
Upside: +5,868.17%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $12.43
Upside: -3.46%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $172.59
Upside: +59.34%